1 Introduction {#S1}
==============

ECM is composed of secreted molecules (glycoproteins, collagens, glycosaminoglycans and proteoglycans) that constitute the cell microenvironment ([@R22]). ECM provides structural support and segregation for different tissues *in vivo*. In the skin, it is essential to the tensile strength and flexibility in the dermis and basement membrane ([@R28]). The basement membrane also acts as a mechanical barrier to cell migration into and out of the epidermis and as a filter of fluid and solute exchange.

However, ECM provides much more than just mechanical and structural support. Multiple specific domains in ECM can bind interacting partners such as other ECM molecules, GFs, cell ECM receptors, e.g. integrins, and other cell surface receptors including some GF receptors. Through such domains, ECM regulates the nature, intensity, and duration of GF signaling. This in turn determines cell behavior, polarity, migration, differentiation, proliferation, and survival ([@R25]; [@R31]).

Many clinical trials in GF-based tissue engineering have been largely disappointing. Recently preclinical studies have shown benefit when GF carriers, such as ECM GF-binding domains, were included in tissue-engineering constructs ([@R11]; [@R19]; [@R36]; [@R37]). These data underline the importance of spatial and temporal regulation of GF signaling to achieve tangible therapeutic effects. Thus, it is critical to understand mechanisms by which ECM can regulate GF signaling in both normal and pathological conditions. Here we review some new findings on fibronectin (FN) interactions with GF in the context of general ways ECM can modulate GF signaling. A more detailed description of ECM and GF interactions can be found in an earlier review by our group ([@R35]).

2 ECM can regulate GF signaling based on ECM-GF binding {#S2}
=======================================================

An increasing number of GFs, including IGF, FGF, TGF-β, HGF, and PDGF have been found to associate with the ECM through growth factor-binding sites ([@R22]). Some of these growth factor-binding sites are conserved across different ECM proteins, e.g. VWC domain in collagen II binds TGF-β1 and BMP-2; heparin II domain in FN binds FGF, VEGF and PDGF ([@R37]; [@R68]); and the FN first type III repeat (FNIII~1~) binds PDGF-BB ([@R33]). A generally held view is that ECM acts as a sink or reservoir for GFs and may assist in establishing stable gradients of GFs bound to ECM. In addition, GFs bound to ECM (as a solid-phase ligand) can generate different signals compared to their soluble form ([@R44]). Proteolytic processing of ECM can release matrix-sequestered GFs during injury or inflammation ([@R3]) inducing rapid and localized changes in the activity of these GFs. Some of these growth factor-binding domains are cryptic and will only be exposed upon proteolytic processing or by the tension force generated by cells (Lin and Clark, unpublished observations).

2.1 ECM as reservoir for GF {#S3}
---------------------------

There is increasing evidence for specific, direct binding of GFs to ECM in general ([@R35]) and to multiple growth factor-binding domains in FN ([@R33]; [@R37]; [@R68]). The ECM can serve as a GF reservoir and increase its local bioavailability ([Figure 1a](#F1){ref-type="fig"}). Hepatocyte growth factor (HGF) binds both FN and vitronectin and forms complexes with HGF receptor and integrins, leading to enhanced cell migration ([@R49]). Similarly VEGF binds to specific FN type III domains in both FN and tenascin-C. Using recombinant FN domains, the C-terminal heparin-II domain of FN (FNIII~13--14~) was identified as a key VEGF-binding site. Mutation of the heparin-binding residues on FNIII~13--14~ abolished VEGF binding, and peptides corresponding to the heparin-binding sequences in FNIII13-14 inhibited VEGF binding to FN. These ECM associations with VEGF synergize to promote cell proliferation ([@R24]; [@R68]). More recently it was found that FN III12--14 binds most of the GFs from the platelet-derived growth factor (PDGF)/VEGF and FGF families and some GFs from the transforming growth factor-β and neurotrophin families ([@R37]). In fibrin matrices functionalized with FN III12--14, PDGF-BB-induced smooth muscle spheroid sprouting was greatly enhanced. Furthermore, enzymatic release of ECM-sequestered GFs during inflammatory processes, including wound healing, can release such GFs ([@R3]). Thus, rapid and local growth factor-mediated activation of cellular functions can occur without de novo synthesis ([@R8]).

2.2 Solid-phase presentation of GF {#S4}
----------------------------------

When tethered to a solid substrate, EGF is more potent than soluble EGF in eliciting DNA synthesis ([@R29]). EGF presented in solid-phase is not internalized and degraded, but instead provides sustained signaling. For example, tethered EGF promoted mesenchymal stem cell (MSC) survival by causing sustained cell surface EGFR activation ([@R52]). Furthermore, the ability of tethered EGF to restricted signaling to the cell surface promoted osteogenic differentiation of multipotent marrow stromal cells ([@R47]). Most interesting, addition of soluble EGF to cells cultured on tethered EGF substrata reduced osteogenic differentiation. Furthermore, soluble EGF down-regulated EGFR and HER2 demonstrating that soluble EGF can modulate tethered EGF/EGFR interactions.

In a similar fashion FN-growth factor-binding domains (FNIII~1~, FNIII~13--14~, and IIICS) enhanced PDGF-BB survival signals in FN-null fibroblasts only when they were surface-bound ([@R33]). These FN domains contain sequence similarities that bind PDGF-BB ([@R34]) as well as VEGF, FGF-2, and TGF-β1 (Lin et al., manuscript in preparation). Therefore, ECM tethered GFs are fine-tuned to generate enhanced and/or distinct signals from their soluble counterparts ([Figure 1b](#F1){ref-type="fig"}).

2.3 Formation of adhesion complexes {#S5}
-----------------------------------

GFR and integrin have been shown to form signaling complexes through various mechanisms ([@R15]; [@R46]). Thus, it is also possible that growth factor-binding domains in ECM proteins can serve as the link that brings together GFR and integrin ([Figure 1c](#F1){ref-type="fig"}) as proposed previously by our group ([@R33]). For example, the α5β1 cell-binding domain (FNIII~9--10~/FNIII~8--11~) and a growth factor-binding domain (either FNIII~1~ or FNIII~12--14~/FNIII~12--15~) only demonstrated synergistic effects when the binding domains for α5β1 and GF were coupled or presented on the same surface - presentation on two separate surfaces did not suffice ([@R33]; [@R38]; [@R68]). For example, FN-null fibroblasts cultured on recombinant FNIII~8--11~ without a FN-growth factor-binding domain (FNIII~1~ or FNIII~12--15~) demonstrated minimal metabolism and underwent autophagy at 24 hours even in the presence of PDGF-BB ([@R33]). In contrast, FN-null fibroblasts plated on FNIII~8--11~ contiguous with a FN-growth factor-binding domain survived without, and proliferated with, PDGF-BB. These results suggest that the mechanism of GF/FN synergism is mediated outside of the cell by the formation of a GF/FN complex requiring both the cell-binding and VEGF-binding domains linked in a single molecular unit. Since such proximity is important, ECM molecules, by virtue of their ordered-domain organization, could act to organize focal adhesion complexes that contain not only integrins, but also growth factor receptors, in the plane of the membrane as previously suggested by results from the Ingber ([@R48]) and Yamada ([@R43]) groups. Such complexes could enhance membrane-proximal regulation among receptors and promote integration of transduced signals ([@R22]; [@R33]).

2.4 Tension force by cell exposes cryptic domain in ECM {#S6}
-------------------------------------------------------

ECM is not an inanimate, unchanging assemblage of collagens, proteoglycans, and glycoproteins. Rather the ECM undergoes constant remodeling, most obviously during development, wound healing, and other repair processes. Furthermore, many ECM molecules are flexible and extendable. Mechanical tension studies on FN suggest that while eliminating normally exposed sites, cell-driven extension of FN can expose cryptic sites that are not available in its native state ([@R64]). Indeed, FN fibrillogenesis requires strain on FNIII~1~ and FNIII~10~ to expose cryptic sites ([@R74]). Such cell-driven strain on FN requires α5β1-binding to the FN central cell-binding domain (FNIII~9--10~) ([@R45]) that is normally exposed on FN in a relaxed state ([@R64]). Two classes of VEGF binding sites on FN have been identified ([@R42]). One is constitutively available whereas the availability of the other was modulated by the conformational state of FN. Atomic force microscopy studies revealed that heparin and hydrophilic substrates promoted an extended conformation of FN, leading to increased VEGF binding. Treatment of the complex endothelial ECM with heparin also increased VEGF binding, suggesting that heparin/heparan sulfate might regulate VEGF interactions within the ECM by controlling the structure and organization of FN matrices. Recent results from our laboratory also strongly support the need of cell tension on FN to expose a cryptic FN peptide for optimal cell survival on intact FN (Lin and Clark, unpublished observations).

2.5 ECM peptides as co-factor of GF {#S7}
-----------------------------------

In venous thrombus resolution, proteolytic fragments of FN, which contain a VEGF binding site, are expressed in a distinct spatial and temporal pattern ([@R14]). Thus, FN may influence capillary morphogenesis by generation of fragments that modulate VEGF stimulated proliferation, migration, and protease activation ([Figure 1d](#F1){ref-type="fig"}). An analysis of FN fragments (Fnf) generated by proteolytic processing from matrix metalloprotease-2 (MMP-2) showed that Fnf of 30-kD and 120-kDa size positively affected proliferation of microvascular cells but not macrovascular cells ([@R20]). Furthermore, a 45-kDa gelatin-binding fragment of FN inhibited retinal endothelial cell proliferation but stimulated pericyte and smooth muscle cell proliferation. Our group has recently identified a bioactive FN peptide P12 from FNIII~1~ ([@R34]) that is theoretically released during proteolysis as part of a larger fragment. Soluble P12 binds PDGF-BB with high affinity (KD in the nanomolar range) and can synergistically promote human dermal fibroblast cell survival by augmenting PDGFR activation and survival signals, i.e. Akt phorphorylation. Moreover, P12 can also affect the PDGF-BB/PDGFR route of endocytosis ([@R75]). When P12 was present, GFP-PDGFR co-localized with a macropinosome marker (70kD-dextran). Results suggested that P12 shifted entry of PDGF-BB from clathrin/caveolin-mediated endocytosis to a macropinocytosis-like pathway and thereby enhanced PDGFR retention before lysosomal degradation. This introduces another layer of interaction/synergism between ECM and growth factor signaling: peptides generated by proteolytic processing of ECM can regulate GF signaling by affecting GF endocytosis.

3 ECM can regulate GF signaling independent of ECM-GF binding {#S8}
=============================================================

All animal cells express receptors for GFs and ECM molecules ([@R25]). GFs have cell-surface receptors that are linked to cellular signaling machinery while adhesion receptors link the cell cytoskeleton to their surroundings, i.e. ECM or other cells, and concomitantly activate signaling pathways. Therefore, the fate of a cell is dependent on signals generated by both receptor systems and the integration between them. In this section we discuss how ECMs with different chemical and physical properties regulate GF signaling independent of ECM-GF binding.

3.1 ECM and GF collaborate to activate the same pathway {#S9}
-------------------------------------------------------

Signals triggered by cell adhesion receptors, such as integrin, are distinct but overlap with GFR signaling pathways ([Figure 2a](#F2){ref-type="fig"}). Signals from both receptor types can converge on the same signaling pathways, e.g. Ras-MAPK pathway, PI3K-Akt pathway, Rho family GTPases ([@R57]; [@R70]). One of the converging points between ECM and GF signaling is focal adhesion kinase (FAK) ([@R23]). It was well established that integrin-mediated cell attachment to ECM triggers FAK activation that is required for integrin-stimulated signaling ([@R60]). However, FAK is required to integrate, at least some, integrin and GF signals ([@R59]). Cells deprived of FAK are refractory to motility signals from EGF while re-expression of FAK rescues these defects. At the same time, efficient EGF-stimulated migration also requires FAK for integrin-receptor clustering. In another scenario, interaction between integrin and PDGFR was demonstrated to be tissue transglutaminase-dependent ([@R72]).

3.2 ECM conditions cells for GF signaling {#S10}
-----------------------------------------

Anchorage dependence refers to a cell\'s requirement of adhesion for cell survival ([@R21]; [@R53]). It is widely appreciated that adherent cells depend on integrin-mediated adhesion for responsiveness to GFs ([Figure 2b](#F2){ref-type="fig"}). Loss of adhesion in normal cells results in growth arrest or anoikis owing to impaired signaling from GFs and cytokines ([@R9]; [@R56]). For example, PDGF stimulated ERK2 activation in fibroblasts is dependent on attachment to FN ([@R51]). However, recent reports suggest that GF signaling can occur in anchorage-independent conditions. For example, IGF1 signals were more clearly detectable in anchorage-independent conditions (poly 2-hydroxyethyl methacrylate-coated plates) than in anchorage-dependent conditions. IGF signaling required αvβ3 integrin expression, and mutant IGF that cannot bind αvβ3 was defective in inducing signals in polyHEMA-coated plates. These results suggest that αvβ3-IGF1 interaction, not αvβ3-ECM interaction, is essential for IGF signaling ([@R15]; [@R16]).

Besides anchorage dependence, different ECM can condition the cell to generate different responses to the same GF. For example, ligation of α5β1 integrin to FN results in Rac activation and cell-cycle progression, whereas α2β1-mediated adhesion to laminin in the same cells results in growth arrest ([@R6]; [@R40]). As another example, primary mammary epithelial cells treated with insulin are protected from cell death when plated on laminin, tenascin C or collagen IV, but not on collagen I ([@R39]; [@R61]). The protective effects of insulin are dependent on the ability of the integrin to promote activation of Akt/PKB in collaboration with insulin receptors.

The physical property of ECM can also condition cells to generate different responses ([@R10]). For example, ECM stiffness has been recognized to provide critical clues for stem cell differentiation ([@R11]; [@R17]). Cellular responses to mechanical signals include differentiation, migration, proliferation, and alterations in cell--cell and cell--matrix adhesion. This "stiffness sensing" has been demonstrated in a variety of cell types including endothelial cells ([@R7]), smooth muscle cells ([@R12]), transformed cells ([@R32]) and stem cells ([@R13]). Stiff substrates increase both focal adhesion and cytoskeletal organization ([@R12]; [@R18]; [@R67]; [@R71]) and conditions cells to GF stimulation. For example, matrix stiffening sensitizes epithelial cells to EGF and enables loss of contact inhibition ([@R27]). A moderate (4.5-fold) stiffening of matrix reduces threshold amount of EGF needed to override contact inhibition. ECM stiffness also primes the TGFβ pathway to promote chondrocyte differentiation ([@R2]).

3.3 ECM can activate GFR in the absence of GF {#S11}
---------------------------------------------

In the absence of GFs, some ECMs can activate GFR on their own through integrin signaling. For example, FNIII~9--10~ (the RGD-containing central cell-binding domain) mediates FN-binding to cells and generates important survival signals either through α5β1 integrin ([@R73]) or by activating GFR ([@R58]). Furthermore, cell adhesion to FN induces α5β1 -dependent phosphorylation of PDGFR-β in the absence of GF stimulation ([@R63]). Similarly, GF-independent activation of c-Met by FN binding to α5β1 occurs in various systems ([@R41]; [@R66]). In another system, activation of integrin α5/β1 by FN could also activate EGFR independent of EGF ([@R30]). This EGFR transactivation was proposed to be mediated by Src dependent Tyr-845 phosphorylation on EGFR ([@R4]). In addition, some bioactive domains within other ECM molecules (matrikines) can activate GFR independent of integrin binding ([@R62]) ([Figure 2c](#F2){ref-type="fig"}). For example, EGF-like domains from laminin ([@R54]) or tenascin ([@R26]) presented as soluble ligands can bind to EGFR and stimulate signaling.

3.4 ECM signaling can regulate GF and GFR expression level {#S12}
----------------------------------------------------------

As an example of ECM regulation of GF level ([Figure 2d](#F2){ref-type="fig"}), the extra domain A (EDA) of FN increases VEGF-C expression in colorectal carcinoma ([@R69]). Furthermore, blocking β1-integrin signaling with antibody caused a down-regulation of EGFR expression level in mammary epithelial cells cultured in three-dimensional basement membrane gels ([@R65]). This does not happen when cells were cultured in two-dimensional matrix, indicating that GFR and integrin couple in a three-dimensional environment. EGFR expression can be regulated by β1 integrin signaling and is reduced when cells are detached from ECM ([@R50]). Also, cell adhesion to ECM inhibits PDGFR degradation thus increases PDGFR ([@R5]) and a low concentration of RGD-mimetic promote VEGF stimulated angiogenesis by increasing VEGFR-2 recycling ([@R19]).

4. Conclusion and future perspectives {#S13}
=====================================

Intensive research has demonstrated that ECM and GF signaling collaborate at many different levels. ECM signaling often synergizes with GF signaling by activating the same pathways. The type and stiffness of ECM condition the cell and regulate the outcome of GF signaling. Some ECM can activate GFR in the absence of GF. The expression level of GFR is regulated by ECM signaling.

Recently, many growth factor-binding domains have been discovered in FN, introducing a new layer of interaction between ECM and GF. First, FN acts as a reservoir of GF and thereby forms GF gradients. Proteolytic processing of FN can release GF deposited in FN while at the same time generate bioactive growth factor-binding peptides. FN tethered GFs are presented as solid phase ligand that retards GFR internalization regulating the duration and outcome of GF signaling. Also, juxtaposition of growth factor-binding domain and integrin binding site in FN facilitates formation of adhesion complex, a structural basis of ECM-GF synergistic signaling. Cells exert tension force on FN that can expose cryptic sites that activate GFR or bind GF. Recently our lab demonstrated FN peptide could regulate GF/GFR trafficking thus affecting GF signaling.

Difficult to heal or chronic wounds exhibit FN deficits and GF abnormalities that likely contribute to their stalled progression. Wound healing strategies that incorporate both FN or other ECM and GF may be beneficial for these wound types and, indeed, therapies of only one type or the other have generally proved disappointing ([@R1]). Future research designed to understand ECM regulation of GF signaling in normal wound healing process may provide important insights in GF/ECM-based tissue engineering ([@R55]).
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![ECM regulation of GF signaling dependent on ECM-GF binding\
a) ECM serves as a reservoir of GF to spatially regulate its bioavailability. b) GF tethered to ECM through growth factor-binding domain is presented as solid phase ligand that generates protracted signaling. c) The juxtaposition of growth factor-binding domain and integrin binding site in ECM facilitates the formation of adhesion complexes, the structural basis for the synergistic signaling of ECM and GF. d) Proteolytic processing not only releases ECM sequestered GF; it also generates bioactive peptides that can directly bind GF and enhance GF signaling.](nihms538986f1){#F1}

![ECM regulation of GF signaling independent of ECM-GF binding\
a) ECM and GF generate signals that activate the same pathway synergistically. b) The type or stiffness of ECM pre-conditions the cell and regulates the outcome of GF signaling. c) ECM can also activate GFR in the absence of GF either through integrin or direct binding to GFR. d) ECM generates signals through integrin to regulate the expression level (recycling) of GFR or GF.](nihms538986f2){#F2}
